Hudson Bay Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hudson Bay Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-90,000	Closed	-$8.17M	–	398
2017 Q2	$8.17M	Buy	+90,000	New	+$8.19M	0.16%	132
2017 Q1	–	Sell	-25,000	Closed	-$2.07M	–	796
2016 Q4	$2.07M	Buy	+25,000	New	+$2.15M	0.04%	343
2015 Q4	–	Sell	-30,000	Closed	-$3.16M	–	188
2015 Q3	$3.16M	Buy	+30,000	New	+$4.01M	0.14%	98

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hudson Bay Capital Management's BMRN Position: Q1 2026 in Review

Hudson Bay Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 45% in Q1 2026, buying an estimated $17.8M and bringing the position to 974,776 shares worth $55.1M. The position accounts for 0.19% of the portfolio, ranked #94.

Hudson Bay Capital Management first reported a position in BMRN in Q1 2015 and has held it in 45 quarters since. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Hudson Bay Capital Management held 974,776 shares of BioMarin Pharmaceuticals worth $55.1M as of Q1 2026.
Hudson Bay Capital Management bought 304,774 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $17.8M.
BioMarin Pharmaceuticals made up 0.19% of Hudson Bay Capital Management's portfolio in Q1 2026, its #94 holding.
Hudson Bay Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 45 quarters since.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.